Basel, 17 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from two phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 and 1 ...
DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal ...
TipRanks on MSN
Genentech presents new Phase 3 data for vamikibart
G enentech, a member of the Roche Group, announced results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart compared with a ...
Researchers have received a $2.2 million grant from the National Institute on Aging of the National Institutes of Health to ...
Patients with age-related macular degeneration may have “transient” adverse macular changes after cataract surgery, but these ...
Age-related macular degeneration is a leading cause of blindness and affects over 196 million people worldwide. Despite its prevalence, very little is known about the causes or mechanisms of this ...
EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding ...
A new study in the journal of Ophthalmology Retina showed that diabetic macular edema (DME) affected 11.1% of people with ...
Verywell Health on MSN
What Vitamin A Can Do for Your Vision, Cancer Risk, and Overall Health
Vitamin A is essential for body functions, including supporting vision and the immune system. You get it as provitamin ...
A real-world analysis has confirmed the negative impact on patients when they lose copay assistance for treatments for retina and macular disease. Presented today during a session at the annual ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback